Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
15 Apr 24
S-3ASR
Automatic shelf registration
21 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
15 Feb 24
8-K
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
8 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
21 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
2 Nov 23
8-K
Entry into a Material Definitive Agreement
23 Oct 23
424B5
Prospectus supplement for primary offering
20 Oct 23
FWP
Free writing prospectus
18 Oct 23
424B5
Prospectus supplement for primary offering
17 Oct 23
8-K
Results of Operations and Financial Condition
16 Oct 23
8-K
Departure of Directors or Certain Officers
8 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
3 Aug 23
8-K
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
12 Jul 23
8-K
Regulation FD Disclosure
6 Jul 23
8-K
Departure of Directors or Certain Officers
13 Jun 23
S-8
Registration of securities for employees
8 Jun 23
8-K
Phase 3 sites beginning to screen patients
5 Jun 23
8-K
Other Events
17 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
4 May 23
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
8-K
Departure of Directors or Certain Officers
23 Mar 23
8-K
Departure of Directors or Certain Officers
14 Mar 23
S-8
Registration of securities for employees
16 Feb 23
10-K
2022 FY
Annual report
16 Feb 23
8-K
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
16 Feb 23
8-K
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
6 Jan 23
8-K
Departure of Directors or Certain Officers
10 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
2 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
28 Oct 22
8-K
Departure of Directors or Certain Officers
15 Sep 22
Latest ownership filings
4
Eric Crombez
19 Apr 24
4
Theodore Alan Huizenga
18 Apr 24
4
Thomas Richard Kassberg
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
Matthew K Fust
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
4
Howard Horn
5 Mar 24
4
Karah Herdman Parschauer
5 Mar 24
4
Thomas Richard Kassberg
5 Mar 24
4
Dennis Karl Huang
5 Mar 24
4
John Richard Pinion
5 Mar 24
4
Theodore Alan Huizenga
5 Mar 24
4
Eric Crombez
5 Mar 24
4
Erik Harris
5 Mar 24
4
EMIL D KAKKIS
5 Mar 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
SANDS CAPITAL MANAGEMENT, LLC
13 Feb 24
4
EMIL D KAKKIS
8 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
144
Notice of proposed sale of securities
7 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
4
EMIL D KAKKIS
2 Jan 24
4
Theodore Alan Huizenga
2 Jan 24
144
Notice of proposed sale of securities
29 Dec 23
4
Thomas Richard Kassberg
24 Oct 23
4
EMIL D KAKKIS
23 Oct 23
144
Notice of proposed sale of securities
23 Oct 23
144
Notice of proposed sale of securities
19 Oct 23
4
Howard Horn
10 Oct 23
3
Howard Horn
10 Oct 23
4
Theodore Alan Huizenga
29 Sep 23
4
Eric Crombez
29 Sep 23
4
Theodore Alan Huizenga
11 Sep 23
SC 13G/A
VANGUARD GROUP INC
11 Sep 23
144
Notice of proposed sale of securities
7 Sep 23
4
Erik Harris
6 Sep 23
4
Theodore Alan Huizenga
6 Sep 23
144
Notice of proposed sale of securities
5 Sep 23